In conclusion, our studies reveal the potential novel use of nasal delivery of CRH in control of overt inflammatory responses localized along respiratory tissues with the potential in reducing mortality risks associated with pneumococcal infection. The gene discussed is CRH; the disease is pneumococcal infection.